Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Up 28.6% in March

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a large increase in short interest in March. As of March 13th, there was short interest totaling 23,175 shares, an increase of 28.6% from the February 26th total of 18,020 shares. Based on an average trading volume of 120,867 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of analysts have commented on XTNT shares. Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. BTIG Research cut their target price on Xtant Medical from $1.50 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $1.00.

Trending Headlines about Xtant Medical

Here are the key news stories impacting Xtant Medical this week:

• Positive Sentiment: Strong FY2025 results: full-year revenue of $133.9M (up 14% YoY), positive net income, adjusted EBITDA and operating cash flow; $17.3M cash on hand plus $10.5M received after year-end tied to a divestiture. Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Q4 beat / strong revenue growth highlighted on the earnings call — underlying operating performance was solid, which supports longer-term recovery if management navigates the divestiture impact. Q4 2025 Earnings Call Highlights
• Positive Sentiment: Analyst stance: BTIG cut its price target from $1.50 to $1.00 but kept a “buy” rating, signaling continued analyst conviction in upside despite lower near-term guidance. BTIG Research note (Benzinga)
• Neutral Sentiment: Full earnings call transcript available for investors wanting granular detail on revenue drivers, divestiture timing and margin outlook. Earnings Call Transcript
• Negative Sentiment: 2026 guidance trimmed: management outlined a $95M–$99M revenue outlook for 2026, explicitly citing the Companion Spine divestiture and the expiration/roll-off of Q-code license revenue — this guidance is the primary reason shares moved lower. Xtant outlines $95M-$99M 2026 revenue outlook
• Negative Sentiment: Immediate market reaction: reports note shares fell following the weak 2026 outlook despite the quarter beat, reflecting investor concern over near-term revenue headwinds. Xtant shares drop nearly 5%
• Negative Sentiment: Short interest rising: data show a notable increase in short interest, which can add downward pressure or increase volatility until visibility on 2026 revenue improves. Sees Large Growth in Short Interest

Xtant Medical Stock Up 2.8%

Shares of NYSEAMERICAN XTNT opened at $0.56 on Wednesday. Xtant Medical has a one year low of $0.34 and a one year high of $0.95. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.21 and a quick ratio of 1.06. The business’s fifty day moving average price is $0.60 and its 200-day moving average price is $0.67. The stock has a market capitalization of $78.12 million, a PE ratio of 55.86 and a beta of -0.30.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Tuesday, March 31st. The medical device company reported $0.03 earnings per share for the quarter. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.The company had revenue of $32.36 million during the quarter, compared to analyst estimates of $30.75 million.

Institutional Trading of Xtant Medical

A number of institutional investors have recently modified their holdings of the business. Nantahala Capital Management LLC boosted its holdings in Xtant Medical by 500.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after buying an additional 57,000,000 shares during the period. AWM Investment Company Inc. bought a new stake in Xtant Medical during the 2nd quarter valued at $4,875,000. Hillsdale Investment Management Inc. bought a new stake in Xtant Medical during the 4th quarter valued at $284,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Xtant Medical during the fourth quarter worth $220,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Xtant Medical by 28.8% in the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after acquiring an additional 205,945 shares during the period. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.